医学
肥胖
更安全的
大流行
糖尿病
风险分析(工程)
重症监护医学
2型糖尿病
超重
人口
生物信息学
2019年冠状病毒病(COVID-19)
疾病
环境卫生
计算机科学
内科学
内分泌学
计算机安全
传染病(医学专业)
生物
作者
Maximilian Kleinert,Christoffer Clemmensen,Susanna M. Hofmann,Mary Courtney Moore,Simone Renner,Stephen C. Woods,Peter Huypens,Johannes Beckers,Martin Hrabě de Angelis,Annette Schürmann,Mostafa Bakhti,Martin Klingenspor,Mark L. Heiman,Alan D. Cherrington,Michael Ristow,Heiko Lickert,Eckhard Wolf,Peter J. Havel,Timo D. Müller,Matthias H. Tschöp
标识
DOI:10.1038/nrendo.2017.161
摘要
Animal models are necessary for the discovery, validation and optimization of novel therapeutics. Here, Matthias Tschöp and colleagues consolidate the key information on the currently available animal models of obesity and diabetes mellitus and highlight the advantages, limitations and important caveats of each of these models. More than one-third of the worldwide population is overweight or obese and therefore at risk of developing type 2 diabetes mellitus. In order to mitigate this pandemic, safer and more potent therapeutics are urgently required. This necessitates the continued use of animal models to discover, validate and optimize novel therapeutics for their safe use in humans. In order to improve the transition from bench to bedside, researchers must not only carefully select the appropriate model but also draw the right conclusions. In this Review, we consolidate the key information on the currently available animal models of obesity and diabetes and highlight the advantages, limitations and important caveats of each of these models.
科研通智能强力驱动
Strongly Powered by AbleSci AI